Based upon a successful engagement with the US Food and Drug Administration (FDA) at the End-of-Phase 2 meeting in January ...

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for ...

The researchers tested their new itaconate-based prodrugs in mice and found that at least two of them were highly effective. The treatment was well-absorbed, reduced inflammation, and stimulated hair ...

Researchers have developed a compound that could potentially treat the autoimmune disorder alopecia, which causes hair loss ...

A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and ...

A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and Louis Garza at Johns Hopkins ...

A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and ...

Researchers have developed a compound that could potentially treat the autoimmune disorder alopecia areata, which causes hair ...

Antimalarial drug resistance is a pressing issue in combating the spread of malaria worldwide. In a new study, researchers discovered a key process where malarial parasites take up a human blood cell ...

However, one promising strategy for drug development is the use of prodrugs, which are used to improve a drug's ability to be absorbed or reach its target. Prodrugs work like a Trojan horse in that ...

Compounding this challenge, malarial parasites have become resistant to nearly every available antimalarial treatment. While a class of drugs known as artemisinin-based combination therapies (ACT) has ...